New cocktail of drugs shows promise for rare, aggressive tumors

NCT ID NCT06232564

Ongoing Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing a combination of chemotherapy (carboplatin and etoposide) with immunotherapy (pembrolizumab), followed by maintenance therapy with pembrolizumab and lenvatinib, in 20 people with advanced high-grade neuroendocrine tumors who have not had prior chemotherapy. The goal is to see if this approach can shrink tumors and improve outcomes. The study is active but no longer recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab, carboplatin, etoposide, and lenvatinib
What this could lead to: If successful, this could offer a new treatment option that shrinks tumors and delays progression for people with advanced high-grade neuroendocrine tumors.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The combination of drugs can cause significant side effects, and it's unclear if it will work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Imperial College Healthcare NHS Trust

London, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.